bioRxivMolecular BiologyPreprint
Sialic acid and fucose residues on the SARS-CoV-2 receptor binding domain modulate IgG reactivity
Ebba SamuelssoniD, Ekaterina E. MirgorodskayaiD, Kristina Nyström, Malin BäckströmiD, Jan‐Åke LiljeqvistiD, Rickard NordéniD
Abstract
The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is a conserved domain and a target for neutralizing antibodies. We defined the carbohydrate content of recombinant RBD produced in different mammalian cells. We found a higher degree of complex type N-linked glycans, with less sialylation and more fucosylation, when the RBD was produced in Human embryonic kidney cells compared to the same protein produced in Chinese hamster ovary cells. The carbohydrates on the RBD proteins were enzymatically modulated and the effect on antibody reactivity was evaluated with serum samples from SARS-CoV-2 positive patients. Removal of all carbohydrates diminished antibody reactivity while removal of only sialic acids or terminal fucoses improved the reactivity. The RBD produced in Lec3.2.8.1-cells, which generate carbohydrate structures devoid of sialic acids and with reduced fucose content, exhibited enhanced antibody reactivity verifying the importance of these specific monosaccharides. The results can be of importance for the design of future vaccine candidates, indicating that it might be possible to enhance the immunogenicity of recombinant viral proteins.
- organism: human
- assay: proteomics
- research focus: protein structure prediction
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity
Y.-P. Hsu, D. Mukherjee, … B. F. Mann·bioRxiv·Aug 26, 2021
- Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells
C. Gstoettner, T. Zhang, … E. Dominguez-Vega·bioRxiv·Feb 23, 2021
- Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
- An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
B. D. Quinlan, W. Li, … M. Farzan·bioRxiv·Nov 18, 2020
- Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation
R. Henderson, R. J. Edwards, … P. Acharya·bioRxiv·Jun 26, 2020
- SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
F. Zhang, F. Schmidt, … P. D. Bieniasz·bioRxiv·Jun 30, 2023